Nanoviricides Stock Price, News & Analysis

NanoViricides (NYSE Amer.:NNVC) will present at the Biotech Showcase™ 2023 Conference in San Francisco on January 9 at 10:30 am PT. Dr. Anil Diwan will discuss the Company’s lead drug candidate, NV-CoV-2, for COVID-19 treatment and its broad-spectrum antiviral platform. This presentation aims to foster partnerships for drug development. The conference, running from January 9-11 at the Hilton San Francisco, is a networking opportunity for life sciences investors and executives.

NanoViricides, Inc. (NYSE Amer. NNVC) announced that its President, Dr. Anil Diwan, will present at the RHK Capital Disruptive Growth Conference in New York City on December 6, 2022, at 1:20 PM ET. The presentation will be accessible via webcast at this link. Dr. Diwan will discuss the lead drug candidate, NV-CoV-2, aimed at treating COVID-19 and long COVID, emphasizing its potential effectiveness against emerging variants.
Furthermore, he will outline the company's pipeline for other viral diseases.

NanoViricides, Inc. (NNVC) filed its Quarterly Report on Form 10-Q for the fiscal first quarter ending September 30, 2022, reporting cash and cash equivalents of approximately $13.1 million and total current liabilities of $0.51 million. The company aims to commence clinical trials for its lead drug candidate NV-CoV-2, designed to treat COVID-19. The IND application is nearing completion, pending engagement with a Clinical Research Organization (CRO). NV-CoV-2 is expected to effectively address COVID-19 and variants due to its broad-spectrum capabilities.

NanoViricides, Inc. (NYSE American: NNVC) filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2022, detailing a current cash balance of approximately $14.4 Million and total current liabilities of $0.41 Million. The company is preparing an IND application for its lead drug candidate, NV-CoV-2, targeting SARS-CoV-2, with plans to conduct human clinical trials. Significant advances include developing an oral solution and a combination therapy with remdesivir. The company also reported a net loss of $8.1 Million for the fiscal year.

NanoViricides, Inc. (NYSE American: NNVC) announced the initiation of drug development targeting the monkeypox virus. The company plans to screen its broad-spectrum antiviral nanoviricides against poxviruses, aiming to create effective therapeutics. Currently, they are nearing completion of compound synthesis and have established a testing model in their lab. Their ongoing clinical trials for the SARS-CoV-2 drug candidate, NV-CoV-2, are expected to expedite this initiative. There is a pressing need for new treatments, especially as monkeypox cases surge globally.

NanoViricides has filed its quarterly report for Q3 of FY 2022, reporting $16 million in current assets and no revenues. With cash liabilities at approximately $0.4 million, the company's stockholder equity stands at $24.75 million. The firm plans to initiate human clinical trials for its COVID-19 drug candidate, NV-CoV-2, which has shown superior efficacy to remdesivir in animal studies. Additionally, it is developing formulations for oral and inhalation delivery. The company is also working on an antiviral for hAd41-F, related to severe hepatitis cases in children.

NanoViricides, Inc. (NYSE American: NNVC) announced the initiation of drug development targeting human Adenovirus 41 Type F, linked to severe pediatric hepatitis cases. This decision follows a rise in worldwide cases, with over 450 reported, including 110 in the USA, where hospitalization exceeds 90%. The company's priority remains advancing NV-CoV-2, its COVID-19 drug candidate, toward clinical trials. NanoViricides plans to screen its antiviral library against hAd41-F using its own BSL2 Virology facility.

NanoViricides, Inc. (NNVC) provided an update on its COVID-19 drug candidate NV-CoV-2, nearing completion of the Investigators Medicinal Product Dossier for clinical trial application. The drug exhibits a novel 'Re-infection Blocker' mechanism and is effective against emerging SARS-CoV-2 variants. The company reports sufficient funding for Phase I/II trials and has developed Oral Gummies to improve patient compliance. Manufacturing systems for clinical trial products are being rapidly established, and the company aims to produce drugs for 1,000-5,000 patients in a single batch.

NanoViricides, Inc. (NNVC) has filed its quarterly report for Q2 FY2022, indicating about $17.5 million in current assets and $0.34 million in current liabilities as of December 31, 2021. The company reports no revenues and approximately $2.84 million used in operations over the six-month period. It is pursuing clinical trials for its COVID-19 drug candidate, NV-CoV-2, which shows promise in pre-clinical studies, being more effective than remdesivir. Additionally, the company is developing formulations for oral gummies and inhalation to improve drug delivery.